FGF2 and neoplasm: Reconciling with the effect of FGF2 ablation, treatment with the neutralizing antibody against FGF2 (3F12E7) significantly reduced popliteal lymph node volume and LNMAC‐transduced tumor burden (Figures 7A–C and S11B, Supporting Information).